Targeting myosin II to alter the disease course of challenging diseases.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40845807.
- Also identified by DOI 10.1016/j.cell.2025.07.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Cell, Kenchappa et al. and Radnai et al. report the development of selective non-muscle myosin II inhibitors that show therapeutic potential in glioblastoma and methamphetamine use disorder, opening new avenues for targeting cell mechanobiology in challenging diseases.
Medical subject headings
- Myosin Type II
- Glioblastoma